Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia

Clinical Transplantation

Volumn 10, Issue 6 I, 1996, Pages 550-555

  Gotti, Eliana ^a,c   Suter, Fredy ^b   Baruzzo, Sara ^c   Perani, Vincenza ^a   Moioli, Fausto ^a   Remuzzi, Giuseppe ^a,c  

^a OSPEDALI RIUNITI   (Italy)

^b Ospedale Provinciale di Busto Arsizo   (Italy)

^c MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Cytomegalovirus infections; Ganciclovir; Kidney transplantation

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FOSCARNET; GANCICLOVIR; VIRUS ANTIGEN;

ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; LEUKOCYTE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIREMIA;

ADOLESCENT; ADULT; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CHEMOPREVENTION; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG MONITORING; DRUG RESISTANCE, MICROBIAL; FEMALE; FOLLOW-UP STUDIES; FOSCARNET; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTES; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE; VIREMIA;

EID: 0030466171     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. TOLKOFF-RUBIN NE, RUBIN RH. Viral infection in the renal transplant recipient. Curr Opin Nephrol Hyperten 1992: 1: 243.
2. HIBBERD PL, TOLKOFF-RUBIN NE, COSIMI AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OTK3. Transplantation 1992: 53: 68.
3. BOWMAN JSIII. ANGSTADT JD. WAYMACK JP, JAFFERS GJ. A comparison of triple therapy with double therapy immunosuppression in cadaveric renal transplantation. Transplantation 1992: 53: 556.
4. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990: 12: S701.
5. PLOTKIN SA, STARR SE, FRIEDMAN HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med 1991: 114:525.
6. LEGENDRE C, ROUZIOUX C, DUCLOUX D, et al. Strategy of cytomegalovirus infection prevention in renal transplantation. Adv Nephrol 1994: 23: 331.
7. MORRIS PJ. Kidney Transplantation: Principles and Practice, London: Grune & Stratton, 1984.
8. BALFOUR HH JR., CHACCE BA, STAPLETON JT, SIMMONS RL, FRYD DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989: 320: 1381.
9. WONG T, TOUPANCE D, CHANARD J. Acyclovir to prevent cytomegalovirus infection after renal transplantation. Ann Intern Med 1991: 115: 68.
10. SINGH N, YU VL, MIELES L, et al. High-dose acyclovir compared with short-course pre-emptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994: 120: 375.
11. MERIGAN TC, RENLUND DG, KEAY S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992: 326: 1182.
12. BAILEY TC, TRULOCK EP, ETTINGER NA, et al. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992: 165: 548.
13. MARTIN M, MANEZ R, LINDEN P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994: 58: 779.
14. POUTEIL-NOBLE C, MEGAS F, CHAPUIS F, et al. Is CMV prophylaxis by ganciclovir-high dose acyclovir worthwhile in renal transplantation? A randomized, controlled, clinical and economical trial. XIIIth International Congress of Nephrol Madrid, July 2-6, 1995: 343. (Abstract)
15. BUHLES WC, MASTRE JB, TINKER AJ, STRAND V, KORETZ SH. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988: 10: S495.
16. SCHMIDT GM, HORAK DA, NILAND JC, et al. A randomized, controlled trsial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogenic bone marrow transplants. N Engl J Med 1991: 324: 1005.
17. GOODRICH JM. MORI M, GLEAVES CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogenic bone marrow transplantation. N Engl J Med 1991: 325: 1601.
18. THE TH, GREFTE JMM, VAN DER Bu W, VAN SON WJ, VAN DEN BERG AP. CMV infection after organ transplantation: immunopathological and clinical aspects. Neth J Med 1994: 45: 309.
19. FARRUGIA E, SCHWAB TR. Subspecialty Clinics: Nephrology. Mayo Clin Proc 1992: 67: 879.
20. THE TH, VAN DER RLOEG M, VAN DEN BERG AP, et al. Direct detection of cytomegalovirus in peripheral blood leukocytes a review of the antigenemia assay and polymerase chain reaction. Transplantation 1992: 54: 193.
21. GROSSI P, MINOLI L, PERCTVALLE E, et al. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995: 59: 847.
22. RUBIN RH. Infectious disease complications of renal transplantation. Kidney Int 1993: 44: 221.
23. PONTICELLI C, TARANTINO G, MONTAGNINO G, et al. A randomized trial comparing triple-drug and double-drug therapy in renal transplantation. Transplantation 1988: 45: 913.
24. VAN DER GIESSEN M, VAN DEN BERG AP, VAN DER Bu W, et al. Quantitative measurement of CMV-specific IgG- and IgM- antibodies in relation to CMV infection. Clin Exp Immunol 1990: 80: 56.
25. VAN DER Bu W, SHIRMAN J, TORENSMAN R, et al. Comparison of viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988: 26: 2531.
26. WINSTON DJ, WIRIN D, SHARED A, BUSUTTIL RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. The Lancet 1995: 346: 69.
27. VAN DEN BERG AP, KLOMPMAKER LJ, HAAGSMA EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991: 164: 265.
28. KELLY JL, ALBERT RK, WOOD DE, RAGHU G. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 1995: 5: 1144.
29. DUNCAN SR, GRGURICH WF, IACONO AT. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Crit Care Med 1994: 150: 146.
30. MAUER JR, SNELL G, DEHOYOS A, KESLEN S, WINTON T. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transpl Proc 1993: 25: 1434.
31. ERICE A, JORDAN MC, CHACE BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. J Am Med Assoc 1987: 257: 3082.
32. SNIDMAN DR, RUBIN RH, WERNER BG. New developments in cytomegalovirus prevention and management. Am J Kidney Dis 1993: 21: 217.
33. SAWYER M, WEB DE, BALOW JE, STRAUSS SE. Acyclovir-induced renal failure. Am J Med 1988: 84: 1067.
34. MCCARTHY JM, KARIN M, KRUEGAR H, KEOWN PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993: 55: 1277.
35. DUNN DL, GILLINGHAM DJ, KRAMER MA, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infections after solid organ transplantation. Transplantation 1994: 57: 876.